rome and Helicobacter-Infections

To evaluate the role of sequential therapy and Lactobacillus reuteri (L. reuteri) supplementation, in the eradication treatment of Helicobacter pylori (H. pylori).. H. pylori infection was diagnosed in 90 adult dyspeptic patients. Patients were excluded if previously treated for H. pylori infection or if they were taking a proton pump inhibitor (PPI), H2-receptor antagonist or antibiotics. Patients were assigned to receive one of the following therapies: (1) 7-d triple therapy (PPI plus clarithromycin and amoxicillin or metronidazole) plus L. reuteri supplementation during antibiotic treatment; (2) 7-d triple therapy plus L. reuteri supplementation after antibiotic treatment; (3) sequential regimen (5-d PPI plus amoxicillin therapy followed by a 5-d PPI, clarithromycin and tinidazole) plus L. reuteri supplementation during antibiotic treatment; and (4) sequential regimen plus L. reuteri supplementation after antibiotic treatment. Successful eradication therapy was defined as a negative urea breath test at least 4 wk following treatment.. Ninety adult dyspeptic patients were enrolled, and 83 (30 male, 53 female; mean age 57 ± 13 years) completed the study. Nineteen patients were administered a 7-d triple treatment: 11 with L. reuteri supplementation during and 8 after therapy. Sixty-four patients were administered a sequential regimen: 32 with L. reuteri supplementation during and 32 after therapy. The eradication rate was significantly higher in the sequential group compared with the 7-d triple regimen (88% vs 63%, P = 0.01). No difference was found between two types of PPI. No difference in eradication rates was observed between patients submitted to L. reuteri supplementation during or after antibiotic treatment. Compliance with therapy was excellent in all patients. No difference in adverse effects was observed between the different antibiotic treatments and between patients submitted to L. reuteri supplementation during and after antibiotic treatment. There was a low incidence of adverse effects in all groups of patients with sequential therapy, probably due to the presence of the L. reuteri supplementation.. The sequential treatment regimen achieved a significantly higher eradication rate of H. pylori compared with standard 7-d regimen. L. reuteri supplementation could reduce the frequency and the intensity of antibiotic-associated side-effects.

Topics: Anti-Bacterial Agents; Breath Tests; Chi-Square Distribution; Combined Modality Therapy; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Limosilactobacillus reuteri; Male; Medication Adherence; Middle Aged; Probiotics; Prospective Studies; Proton Pump Inhibitors; Rome; Time Factors; Treatment Outcome

The Rome IV criteria have been established as an international standard for diagnosing disorders of gut-brain interaction. In this study, we aimed to examine the upper gastrointestinal (GI) endoscopic findings and symptoms of subjects with functional constipation (FC) and irritable bowel syndrome (IBS) of individuals undergoing a medical check-up.. A total of 13,729 subjects underwent a medical check-up at Osaka City University-affiliated clinic, MedCity21, between April 2018 and March 2019. Among the 5,840 subjects who underwent screening upper GI endoscopy and completed a questionnaire based on the Rome IV criteria, 5,402 subjects were consecutively enrolled after excluding subjects with a large amount of gastric residue (n = 6), those who had previously undergone partial or total gastrectomy (n = 40), or those with daily use of low-dose aspirin (n = 82), nonsteroidal anti-inflammatory drugs (n = 63), or acid secretion inhibitors (n = 308).. Robust Poisson regression analyses adjusted for age, sex, Helicobacter pylori infection status, alcohol intake, and smoking habits showed a significant association between FC and corpus erosion (adjusted prevalence ratio [aPR], 2.93; 95% confidence interval [CI], 1.51-5.67; p < 0.01) and red streaks (aPR, 3.83; 95% CI, 2.53-5.79; p < 0.01), whereas IBS was significantly associated with erosive gastritis (aPR, 8.46; 95% CI, 4.89-14.67; p < 0.01) and duodenitis (aPR, 7.28; 95% CI, 3.64-14.59; p < 0.01). Red streaks tended to be associated with IBS (aPR, 1.96; 95% CI, 1.00-3.83; p = 0.05). Subjects with IBS were the most to complain of both upper and lower GI symptoms and psychological symptoms, followed by those with FC and controls. IBS subjects with erosive gastritis or duodenitis had significantly more complaints of stomachache and feeling stressed than those without erosive gastritis or duodenitis (54.5% vs. 18.8%; p = 0.03 and 66.7% vs. 25.0%; p = 0.01).. Subjects with FC and IBS had a variety of upper GI and psychological symptoms. In the upper GI endoscopic findings, corpus erosion and red streaks were associated with FC, and erosive gastritis, duodenitis, and possibly red streaks were associated with IBS.

Topics: Constipation; Cross-Sectional Studies; Duodenitis; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Irritable Bowel Syndrome; Japan; Rome; Surveys and Questionnaires

Topics: Adolescent; Case-Control Studies; Child; Child, Preschool; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Psoriasis; Rome

In an attempt to establish the etiologic role of Helicobacter pylori (H. pylori) in gastric and/or duodenal pathology, 169 patients were tested and compared with a control group of 25 healthy subjects, for a total of 194 subjects. Data on sex, age, familiarity, smoking, coffee and alcohol habits were collected and each patient underwent histological, microbiological and immunological tests. 80 (41.2%) subjects were found positive to H. pylori. This bacterium was detected in 53.3% of patients with gastric ulcer while IgG were found in 86.7%; in 50% of patients with chronic atrophic gastritis while IgG were detected in 80%; in 48.5% of patients with duodenal ulcer while IgG were found in 87.9%; in 41.8% of patients with superficial chronic gastritis while IgG were detected in 80.2%. In the control group of healthy patients H. pylori was found in 28% of patients while IgG were detected in 62.5%. The results do not confirm a direct clear-cut correlation between this microorganism and the pathologies studied.

Topics: Adult; Aged; Aged, 80 and over; Antibodies, Bacterial; Biopsy; Duodenal Ulcer; Endoscopy; Female; Gastritis; Gastrointestinal Diseases; Helicobacter Infections; Helicobacter pylori; Humans; Immunoglobulin G; Incidence; Male; Middle Aged; Peptic Ulcer; Pilot Projects; Risk Factors; Rome